<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01945554</url>
  </required_header>
  <id_info>
    <org_study_id>EKSG 13/061</org_study_id>
    <nct_id>NCT01945554</nct_id>
  </id_info>
  <brief_title>The Value of Short-term Pain Relief for the Prediction of Long-term Outcome After Cervical or Lumbar Nerve Root Infiltration</brief_title>
  <acronym>InfStu</acronym>
  <official_title>The Value of Short-term Pain Relief for the Prediction of Long-term Outcome After Cervical or Lumbar Nerve Root Infiltration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Holger Joswig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cantonal Hospital of St. Gallen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose if this study is to assess the response to nerve root infiltration therapy in
      patients with cervical or lumbar disc herniations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, observational study examines the response to routine infiltration therapy
      in patients suffering from disc herniations of the spine. Using health-related quality of
      life questionnaires (SF-12 and Neck Pain and Disability Scale and Oswestry Disability Index)
      and the visual analogue scale the patients will be categorized into ultra-early-, early-,
      mid-term-, late-responders and non-responders. A two year follow-up of up to 250 patients is
      planned. With the anonymized participation of this study no patient will experience a change
      in his treatment plan. Valuable therapeutic management considerations might be drawn from the
      published results of this study for future patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Health-related quality of life (HRQoL)</measure>
    <time_frame>1 month</time_frame>
    <description>(SF)-12 questionaire Change from Baseline SF-12 at 1 month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neck Pain and Disability Scale (NPAD)</measure>
    <time_frame>Before, 14 days, 1 month, 3 months, 6 months, 12 months, 24 months</time_frame>
    <description>Neck Pain and Disability Scale (NPAD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index (ODI)</measure>
    <time_frame>Before, 14 days, 1 month, 3 months, 6 months, 12 months, 24 months</time_frame>
    <description>Oswestry Disability Index (ODI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change of pain (VAS)</measure>
    <time_frame>Before, 14 days, 1 month, 3 months, 6 months, 12 months, 24 months</time_frame>
    <description>Percent change of pain (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for additional surgical therapy and time-to-surgery.</measure>
    <time_frame>14 days, 1 month, 3 months, 6 months, 12 months, 24 months</time_frame>
    <description>Need for additional surgical therapy and time-to-surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for hospitalization for disabling pain and time-to-hospitalization.</measure>
    <time_frame>14 days, 1 month, 3 months, 6 months, 12 months, 24 months</time_frame>
    <description>Need for hospitalization for disabling pain and time-to-hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for repeated infiltrations and time-to-infiltration between the study groups.</measure>
    <time_frame>14 days, 1 month, 3 months, 6 months, 12 months, 24 months</time_frame>
    <description>Need for repeated infiltrations and time-to-infiltration between the study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute VAS pain reduction of a repeated &quot;boost&quot;-infiltration</measure>
    <time_frame>14 days, 1 month, 3 months, 6 months, 12 months, 24 months</time_frame>
    <description>Absolute VAS pain reduction of a repeated &quot;boost&quot;-infiltration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of opioid use (yes/no)</measure>
    <time_frame>Before, 14 days, 1 month, 3 months, 6 months, 12 months, 24 months</time_frame>
    <description>Frequency of opioid use (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to return to work (0-100%) and time-to-return to work.</measure>
    <time_frame>Before, 14 days, 1 month, 3 months, 6 months, 12 months, 24 months</time_frame>
    <description>Ability to return to work (0-100%) and time-to-return to work.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (HRQoL)</measure>
    <time_frame>Before, 14 days, 1, month, 3 months, 6 months, 12 months, 24 months</time_frame>
    <description>(SF)-12 questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for 2nd infiltration / surgery</measure>
    <time_frame>1 month, 3 months, 6 months, 12 months, 24 months</time_frame>
    <description>Reasons may be either pain and/or sensory dysfunction and/or motor weakness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's satisfaction with therapy</measure>
    <time_frame>14 days, 1 month, 3 months, 6 months, 12 months, 24 months</time_frame>
    <description>Would you opt for an infiltration again (provided you had the same outcome as now)?
certainly yes
maybe yes
unsure
maybe no
certainly no</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Cervical Disc Herniation</condition>
  <condition>Lumbar Disc Herniation</condition>
  <arm_group>
    <arm_group_label>Cervical disc herniation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with cervical disc herniation and compression of nerve roots C3-C8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lumbar disc herniation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with lumbar disc herniation and compression of nerve roots L1-S1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cervical nerve root infiltration</intervention_name>
    <description>4mg Mephamesone followed by 1ml of 0.5% bupivacaine (Bupivacain®) will be administered.</description>
    <arm_group_label>Cervical disc herniation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lumbar nerve root infiltration</intervention_name>
    <description>40mg triamzinolone (Kenacort®) followed by 2ml of 0.5% bupivacaine (Bupivacain®) will be administered.</description>
    <arm_group_label>Lumbar disc herniation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mephamesone</intervention_name>
    <arm_group_label>Cervical disc herniation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% bupivacaine (Bupivacain®)</intervention_name>
    <arm_group_label>Cervical disc herniation</arm_group_label>
    <arm_group_label>Lumbar disc herniation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kenacort®</intervention_name>
    <arm_group_label>Lumbar disc herniation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic (pain) one-level cervical (C3-C8) or lumbar (L1-S1) radiculopathy with
             radiological evidence of discal nerve root compression

          -  Minimum VAS of 20/100

          -  Age between 18 - 70 years

        Exclusion Criteria:

          -  Multilevel disc herniations with multiple symptomatic nerve root compressions

          -  Higher motor deficits (Paresis M 0-3 of a peripheral muscle)

          -  Age &lt; 18 or &gt; 70 years

          -  Pregnancy

          -  Allergic reaction against steroids or local anaesthetic

          -  Bleeding disorder (Tc &lt; 100.000/ul, Quick &lt;50%, INR &gt; 1.5, abnormal PTT)

          -  Known bleeding diathesis

          -  Continued anticoagulants (Warfarin = Marcoumar must be bridged with low- or
             high-molecular heparin; commonly, intake of Aspirin or Clopidogrel is no
             contraindication for infiltration therapy but is routinely paused when possible)

          -  Pseudoradicular pain (e.g. in facet arthrosis, iliosacral arthrosis...) - as evaluated
             to the best of the knowledge of the admitting physician and radiologist performing the
             infiltration

          -  Osseous spinal or foraminal stenosis

          -  Myelopathy

          -  Severe scoliosis

          -  Active neoplasm

          -  History of spinal infection / spondylodiscitis

          -  History of spinal surgery or previous infiltration therapy on the currently painful
             segment

          -  Rheumatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holger Joswig, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cantonal Hospital St. Gallen, Dept. of Neurosurgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Flawil Hospital</name>
      <address>
        <city>Flawil</city>
        <state>Saint Gallen</state>
        <zip>9230</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rorschach Hospital</name>
      <address>
        <city>Rorschach</city>
        <state>Saint Gallen</state>
        <zip>9400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://research.kssg.ch/EXPORT/PDF/Projekt/54360.pdf</url>
    <description>Study synopsis</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2013</study_first_submitted>
  <study_first_submitted_qc>September 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2013</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cantonal Hospital of St. Gallen</investigator_affiliation>
    <investigator_full_name>Holger Joswig</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>infiltrative therapy</keyword>
  <keyword>cervical disc herniation</keyword>
  <keyword>lumbar disc herniation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

